Cannabis Cancer References

These are the references for the article “Cannabis Cures Cancer”?
(1) J. Berthiller, et al., Cannabis Smoking and Risk of Lung Cancer in Men: A Pooled Analysis of Three Studies in Maghreb, Journal Of Thoracic Oncology, Dec 2008, Volume 3, Issue 12, pp 1398–1403.

(2) S. Aldington, et al., Cannabis use and risk of lung cancer: a case–control study, European Respiratory Journal Feb 2008, 31 280-286.

(3) Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The Association Between Marijuana Smoking and Lung Cancer: A Systematic Review, Arch Intern Med, 2006, 166(13) 1359-1367.

(4) R. Callaghan, P. Allebeck, and A. Sidorchuk, Marijuana use and risk of lung cancer: a 40-year cohort study, Cancer Causes & Control, October 2013, Volume 24, Issue 10, pp 1811-1820.

(5) C. Blazquez, et al., Inhibition of tumor angiogenesis by cannabinoids, FASEB J. 2003 Mar, 17(3) 529-31, Epub 2003 Jan 2.

(6) E. Moreno, et al., Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling, The Journal of Biological Chemistry, Aug 8, 2014, 289 21960-21972.

(7) S. Jones and J. Howl, Cannabinoid receptor systems: therapeutic targets for tumour intervention, Expert Opin Ther Targets. 2003 Dec 7, (6) 749-58.

(8) D. Parolaro, et al., Endocannabinoids in the immune system and cancer, Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar, 66(2-3) 319-32.

(9) J. Legault and A. Pichette, Potentiating effect of beta-caryophyllene on anticancer activity of alpha-humulene, isocaryophyllene and paclitaxel, J Pharm Pharmacol. 2007 Dec, 59(12) 1643-7.

(10) R. Musty and R. Rossi, Effects of Smoked Cannabis and Oral Delta 9-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy, Journal of Cannabis Therapeutics, Volume 1, Issue 1, 2001.

(11) J. Ungerleider, et al., Cannabis and Cancer Chemotherapy: A Comparison of Oral Delta-9-THC and Prochlorperazine, Cancer, 1982, 50 636-645.

(12) R. Machado Rocha, et al., Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis, European Journal of Cancer Care, Volume 17, Issue 5, pages 431–443, September 2008.

(13) M. van der Stelt, et al., Neuroprotection by Delta 9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity, The Journal of Neuroscience, 1 September 2001, 21(17) 6475-6479.

(14) M. Guzman, et al., A pilot clinical study of Delta 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme, British Journal of Cancer (2006) 95, 197–203.

(15) C. Sanchez, et al., Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells, FEBS letters, 1998, 9771884.

(16) C. Blazquez, et al., Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas, Cancer Res. 2004 Aug 15;64(16):5617-23.

(17) C. Sanchez, et al., Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor, Cancer Res. 2001 Aug 1;61(15):5784-9.

(18) P. Massi, et al., Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines, JPET March 2004 vol. 308 no. 3 838-845.

(19) S. Torres, et al., A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma, Mol Cancer Ther Jan 2011 10; 90.

(20) K. Scott, A. Dalgleish, and W. Liu, The Combination of Cannabidiol and Delta 9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model, Mol Cancer Ther; 1–13. 2014.

(21) T. Aguado, et al., Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis, J Biol Chem. 2007 Mar 2, 282(9) 6854-62.

(22) M. Caffarel, et al., Cannabinoids: a new hope for breast cancer therapy?, Cancer Treat Rev. 2012 Nov, 38(7) 911-8.

(23) J. Held-Feindt, Cannabinoid receptors in human astroglial tumors, J Neurochem. 2006 Aug, 98(3) 886-93.

(24) M. Caffarel, et al., Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition, Molecular Cancer, 2010, 9 196.

(25) P. Morales, et al., Selective Nontoxic CB2 Cananbinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer, J. Med. Chem., 2015, 58 (5), pp 2256-2264.

(26) M. Elbaz, et al., Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer, Fed. Of Eur. Biochem. Societies, 2015, Vol. 9, Issue 4, pp 906-919.

(27) S. McAllister, et al., Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis, Breast Cancer Res Treat. 2011 Aug, 129(1) 37-47.

(28) S. McAllister, et al., Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells, Mol Cancer Ther. 2007 Nov, 6(11), 2921-7.

(29) A. Ligresti, et al., Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma, JPET May 25, 2006.

(30) M. Nasser, et al., Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion, PLoS One. 2011, 6(9) e23901.

(31) L. Petrocellis, et al., The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 8375–8380, July 1998, Pharmacology.

(32) R. Ramer, et al., Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1, FASEB J. 2012 Apr, 26(4) 1535-48.

(33) A. Preet, et al., Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis, Cancer Prev Res (Phila). 2011 Jan, 4(1) 65-75.

(34) A. Preet, et al., Delta 9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo, Oncogene (2008) 27, 339–346.

(35) D. White, et al., Cannabinoids inhibit cellular respiration of human oral cancer cells, Pharmacology. 2010, 85(6) 328-35.

(36) W. Hall and D. MacPhee, Cannabis use and cancer, Addiction Volume 97, Issue 3, pages 243–247, March 2002.

(37) N. Firth, Marijuana use and oral cancer: a review, Oral Oncology, Volume 33, Issue 6, November 1997, Pages 398–401.

(38) J. Ramos and F. Bianco, The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications, Indian J Urol. 2012 Jan-Mar, 28(1) 9–14.

(39) L. De Petrocellis, et al., Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms, Br J Pharmacol. 2013 Jan;168(1):79-102.

(40) M. Mimeault, et al., Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production, Prostate. 2003 Jun 15, 56(1) 1-12.

(41) A. Carracedo, et al., Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress–Related Genes, Cancer Res July 1, 2006, 66 6748.

(42) S. Sarfaraz., Cannabinoid receptor as a novel target for the treatment of prostate cancer, Cancer Res. 2005 Mar 1, 65(5) 1635-41.

(43) G. Aviello, et al., Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer, J Mol Med (Berl). 2012 Aug, 90(8) 925-34.

(44) Y. Singh and C. Bali, Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation, Case Rep Oncol., 2013 Nov 28, 6(3), pp 585-92.

(45) K. Gustafsson, et al., Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma, Molecular Pharmacology November 2006 vol. 70 no. 5 1612-1620.

(46) K. Gustafsson, et al., Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation, International Journal of Cancer, Volume 123, Issue 5, pages 1025–1033, 1 September 2008.

(47) W. Jia, el al., Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria, Mol Cancer Res. 2006 Aug, 4(8) 549-62.

(48) R. McKallip, et al., Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease, Blood. 2002 Jul 15, 100(2) 627-34.

(49) M. Casanova, et al., Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors, J Clin Invest. 2003 Jan, 111(1) 43-50.

(50) D. Xu, et al., Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells, Mol Med Rep. 2015 Dec, 12(6) 7963-70.

(51) D. Vara, et al., Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy, Cell Death Differ. 2011 Jul, 18(7) 1099-111.

(52) S. Leelawat, et al., The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration, Cancer Invest. 2010 May, 28(4) 357-63.

About Nicco Reggente, PhD 167 Articles
Nicco is the co-founder and CEO of WoahStork and Strain Genie-- two companies dedicated to bringing to life his passion of bringing personalized medicine to the cannabis industry. Nicco received his PhD from UCLA in cognitive neuroscience with a focus on machine learning applied to neuroimaging datasets. He previously received two B.As from NYU in Psychology and Philosophy.